Ira Zackon, MD, discussed his retrospective study which aimed to understand patient characteristics, treatment patterns, and OS of patients with higher-risk MDS treated in the community oncology setting.

Medika’s Top 20 ’24 Influential Voices to Follow
Dave is the world’s first LLM conversational AI oncology mentor for cancer patients, bringing a…